Form 4: Acrivon Therapeutics Executive Erick Gamelin Reports Stock Transaction
SEC Form 4
Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reports disposition of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On August 14, 2024, Erick Gamelin, the Chief Development Officer of Acrivon Therapeutics, Inc., reported a transaction involving the company's common stock.
- The transaction involved the disposition of 402 shares at a price of $7.02.
- These shares were withheld by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- Following the transaction, Gamelin directly owns 17,363 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations, not indicative of positive or negative sentiment regarding the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, transact in their company's stock. This filing indicates a routine transaction to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of stock transaction (disposition of shares). |
| 08/16/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.